WorldWide Asthma and COPD Market, Industry / Sector Analysis Report, Regional Outlook & Competitive Market Share & Forecast, 2019 - 2025 (Includes Business Impact of COVID-19)

                                          
Asthma and COPD Market size is projected to experience significant growth from 2017 to 2024.
 

Rising prevalence of the respiratory diseases, growing pathogens in environment leading to chronic conditions such as, chronic obstructive pulmonary disease (COPD) and asthma are the major growth driving factors. These conditions require lifelong medications as a result medical adherence is extremely necessary, in addition, the reduction in quality of life are some aspects that fuel the asthma and COPD market growth over the forecast period.
 

These chronic respiratory diseases are caused by numerous environmental factors or are genetically acquired requires constant care management. As per WHO in 2015, approximately 3 million deaths were caused due to COPD, being the progressive and life-threatening disease of lungs, this accounts for around 5% of the total global deaths per year.
 

Moreover, the supporting initiatives by private and public institutions adds up to the asthma and COPD market size growth during the forecast timeframe. For instance, the Global Asthma Network (GAN) along with the International Union against Tuberculosis and lung disease and the International Study of Asthma and Allergies in Childhood (ISAAC) aims reduction in asthma suffering. This is done by the improvement in respiratory care globally and are more focused on the low and middle-income nations. The increase in adoption rate of products thereby, provide business growth.
 

COPD and asthma chronic conditions are non-curable and can be controlled with proper diagnosis and care. In addition, novel pharmacologic possibilities are being explored, by concentrating on definite biological mechanism and by knowing pathogenesis of these illnesses. However, the expiration of patents in many blockbuster brands will cause pressure such as high cost of treatment.
 

Anti-inflammatory drugs segment includes anti-leukotrienes, monoclonal antibodies, and corticosteroids. Corticosteroids dominated the segment in 2016, due to increased usage in corticosteroids for COPD and associated advantages with inhaled corticosteroid (ICS) such as high topical force in the direction of decreasing inflammation in low and lung systemic motion.
 

Inhalers includes metered dose inhalers (MDIs), soft mist inhalers (SMIs), and drug powder inhalers (DPIs). DPIs accounted for major share in 2016 due to the advantages such as less patient coordination required, compactness, appropriate for emergency circumstances, and portability are some aspects that encourages the patients’ buying preferences.
 

U.S. led the asthma and COPD market owing to strong pipeline for novel therapies, technological advancements, and growing disease prevalence. According to, the CDC, in 2014, around 15.7 million Americans were detected with COPD, that accounts for 6.4% people of the total population. India and China are growing significantly due to increase in disease prevalence. These nations have opportunity to grow their business rapidly as some of the European pharmaceutical companies are on the edge of expiration in terms of numerous patents.
 

Some of the industry players include F. Hoffmann-La Roche, Boehringer Ingelheim, Cipla, Aurobindo, GlaxoSmithKline, AstraZeneca, Novartis, Ranbaxy, Merck, Pfizer, Glenmark, Abbott, Dr. Reddy’s Laboratories, Nycomed, Amgen, Mylan, Vectura, AptarGroup, Actavis, and Sunovion. The industry players focus on strategic alliances, mergers, and enhanced combination drugs, usage of biologics, as well as personalization in treatment upsurges business growth. For instance, in May 2016, AstraZeneca announced positive results for the benralizumab, potential novel medicine with phase III programme for severe asthma.